Gabrielle Macaron, MD
Staff neurologist, Cleveland Clinic; Hôtel-Dieu de France Hospital, Lebanon
Articles
Factors to Consider When Choosing the Right Disease-Modifying Therapy for Newly Diagnosed MS
August 6th 2025Gabrielle Macaron, MD, assistant professor of neuroscience at Université de Montréal, discussed the nuanced clinical decision-making involved in initiating a DMT for patients newly diagnosed with MS.
Balancing MS Relapse Risk With Personalized Therapy Decisions: Gabrielle Macaron, MD
June 26th 2025The assistant professor in the Department of Neuroscience at Université de Montréal discussed the importance of weighing the risks of multiple sclerosis against treatment risks, emphasizing individualized care. [WATCH TIME: 4 minutes]
Individualizing Disease-Modifying Therapy Selection in Newly Diagnosed MS: Gabrielle Macaron, MD
June 3rd 2025The assistant professor in the Department of Neuroscience at Université de Montréal discussed key clinical factors influencing DMT selection in patients newly diagnosed with multiple sclerosis. [WATCH TIME: 5 minutes]
Investigating Disability and Onset Age in NMOSD: Gabrielle Macaron, MD
February 10th 2021The neurologist from Cleveland Clinic discussed how her study reinforced previous findings that individuals with early onset neuromyelitis optica spectrum disorders are more likely to experience severe vision loss.
